Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | F2 | P00734 | 2/20 | 0.45 |
| ▸ | SPR | P35270 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MGLL | Q99685 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30380803 | 0.95 | KDM4E (0.74) | KDM4EHSD11B1HPGDKMT2AF2 | |
| SCHEMBL23113441 | 0.85 | PHGDH (0.59) | KDM4EHSD11B1HPGDKMT2AF2 | |
| SCHEMBL2014694 | 0.83 | KDM4E (1.00) | KDM4EHSD11B1HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL29944043 | 0.82 | HSD11B1 (0.66) | KDM4EHSD11B1HPGDCNR2KMT2A | |
| SCHEMBL3456204 | 0.82 | HSD11B1 (0.66) | KDM4EHSD11B1HPGDCNR2KMT2A | |
| SCHEMBL2677909 | 0.79 | CNR2 (0.53) | KDM4EHSD11B1HPGDCNR2KMT2A | |
| SCHEMBL3104372 | 0.79 | KDM4E (0.77) | KDM4EHSD11B1HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL13495499 | 0.76 | KDM4E (0.77) | KDM4EHSD11B1HPGDKMT2AALDH1A1 | |
| SCHEMBL22000653 | 0.76 | CNR2 (0.53) | KDM4EHSD11B1HPGDCNR2KMT2A | |
| SCHEMBL21999695 | 0.76 | ACLY (0.51) | KDM4EHSD11B1HPGDCNR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11555012-B2 | ACLY inhibitors and uses thereof | Nimbus Artemis, Inc. (US) | 2023-01-17 | — | — | US | disclosed |
| US-20200148634-A1 | ACLY INHIBITORS AND USES THEREOF | Nimbus Artemis, Inc. | 2020-05-14 | — | — | US | disclosed |
| US-20200148634-A1 | ACLY INHIBITORS AND USES THEREOF | Nimbus Artemis, Inc. | 2020-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200148634-A1 | ACLY INHIBITORS AND USES THEREOF | ACLY, ATP5ME, ATP5MG | KDM4E 1181/4885HSD11B1 2893/4885HPGD 1212/4885 |
| US-11555012-B2 | ACLY inhibitors and uses thereof | ACLY, ATP5ME, ATP5MG | KDM4E 1181/4885HSD11B1 2893/4885HPGD 1212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.